... the exit of non-residents from Russian business: the regulations introduced at the end of 2024 entail hefty fines and additional payments to the budget, totaling up to 95% of the asset value, effectively blocking most transactions involving foreign capital. Secondly, high financing costs diminish project attractiveness: the Bank of Russia's key rate has been raised to 21%, making loans expensive. Thirdly, the uncertainty in the economic situation (geopolitical risks, high sanctions costs, and ruble volatility) complicates revenue and cash flow forecasting for target companies, increasing expected risks. Finally,...

... an IPO, targeting a valuation of up to $5 billion. The stock placement is expected to take place in spring 2025. This move is seen as a signal of the industry's maturation: stablecoins are increasingly recognized by the traditional financial system. Raising capital through the IPO will bolster Circle's financial base and allow it to expand services for institutional clients. Back in 2021, Circle attempted to enter the stock market through a SPAC merger, but the deal fell through in 2022 due to a tougher ...

... national debt unsustainable, spurring discussions among economists and policymakers about possible solutions: Increasing Taxes Raising taxes on corporations and high-income individuals could boost revenue and partially offset the deficit. However, higher ... ... reliant on stable dollar reserves. Global Consequences and Investment Strategies The expanding U.S. debt may reshape global capital flows, underscoring the need for investors to adapt their strategies. Investors may benefit from diversifying their portfolios ...

... reap profits. Conversely, if a company performs poorly, investors risk losing their invested capital. Advantages of Crowdfunding With a large number of participants, the entry threshold is relatively low. This allows even investors without their own capital to begin investing. High potential returns. Thanks to the raised funds, companies can demonstrate dynamic growth while ensuring they reward shareholders for their trust. Valuable connections. Investors have the opportunity to meet many useful contacts in such projects. These connections will undoubtedly prove ...

... growth of new drugs, such as the cardiovascular drug Camzyos and the immunology product Opdualag. In the first quarter, BMS raised its annual revenue forecast, and investors will track whether this trend continues: they await comments on the demand for ... ... drugs and possible progress in clinical trials. An important signal will be the dynamics of debt load and plans for returning capital to shareholders—as BMS is known for generous dividends. If management can convince the market that the company is navigating ...